Return to homepagePandemic Pact

Thrombosis with Thrombocytopenia Syndrome after SARS-CoV-2 vaccination

  • Funded by Netherlands Organisation for Health Research and Development (ZonMW)
  • Total publications:0 publications

Grant number: 1.04301E+13

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2021
    2023

  • Funder

    Netherlands Organisation for Health Research and Development (ZonMW)

  • Principal Investigator

    J. Coutinho

  • Research Location

    Netherlands

  • Lead Research Institution

    Amsterdam UMC Locatie AMC

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Supportive care, processes of care and management

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Thrombosis in combination with a low platelet count occurs in rare cases after vaccination with the COVID-19 vaccines from AstraZeneca and Janssen. Most of these patients developed a thrombosis in the head (sinus thrombosis). The disease is called vaccine-induced immune thrombotic thrombocytopenia (VITT). There are many unanswered questions about VITT, including: 1. How common is VITT? 2. What are the clinical manifestations and prognosis of VITT? 3. Has the prognosis improved after the introduction of international treatment guidelines? 4. How common are PF4 antibodies (the suspected cause of VITT) in healthy people who are vaccinated? 5. What role do the clotting and immune systems play in VITT? The purpose of this research is to answer these questions. We provide doctors and policy makers with scientific evidence that can be used to optimize vaccination strategies and the treatment of patients with VITT.